辛妥珠单抗
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目标 | LOXL2 |
| 临床资料 | |
| ATC码 |
|
| 识别信息 | |
| CAS号 | 1318075-13-6 |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| 化学信息 | |
| 化学式 | C6558H10134N1736O2037S50 |
| 摩尔质量 | 147,492.33 g·mol−1 |
辛妥珠单抗（INN：simtuzumab；开发代号：GS-6624）是一种人源化单克隆抗体，设计用于治疗纤维化。[1]它与LOXL2结合并充当免疫调节剂。[2][3]2016年1月，吉利德科学公司因缺乏疗效而终止了针对特发性肺纤维化（IPF）患者的II期临床研究。[4]
参考资料
[编辑]- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Simtuzumab, American Medical Association.
- ^ Muir, Andrew J.; Levy, Cynthia; Janssen, Harry L. A.; Montano-Loza, Aldo J.; Shiffman, Mitchell L.; Caldwell, Stephen; Luketic, Velimir; Ding, Dora; Jia, Catherine; McColgan, Bryan J.; McHutchison, John G. Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. Hepatology (Baltimore, Md.). 2019-02, 69 (2). ISSN 1527-3350. PMID 30153359. doi:10.1002/hep.30237.
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2).
- ^ Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary Fibrosis. Gilead. 5 January 2016.